Biomarkers of the Toxic Effects of Chemotherapeutic Agents: A Focus on Antimalarials

Audu, David; Petagine, Lucy; Idowu, Olufunmilayo Ajoke; Patel, Vinood B.; Idowu, Adewunmi Babatunde

doi:10.1007/978-3-030-87225-0_73-2

David Audu⁶,
Lucy Petagine⁷,
Olufunmilayo Ajoke Idowu⁶,
Vinood B. Patel⁷ &
…
Adewunmi Babatunde Idowu⁶

Part of the book series: Biomarkers in Disease: Methods, Discoveries and Applications ((BDMDA))

27 Accesses
1 Citations

Abstract

Malaria continues to inflict unacceptably high levels of sickness and mortality, as reported in the previous editions of the World Malaria Report. Antimalarial drugs are the most common treatment for this condition. The gastrointestinal tract, the eyes, the central nervous system, and the cardiovascular system are all affected by antimalarial toxicity; this literature aims to provide an overview of recent advances relating to biomarkers of the toxic effects of antimalarial drugs. Gene polymorphism of metabolizing enzymes; predominantly Cytochrome P450 (CYP) and UDP Glucuronosyltransferase (UGT), drug Transporter; (P-glycoprotein and Organic anion Transporter 1B1), Glutathione S-transferases and deficiency of Glucose-6-Phosphate dehydrogenase (G6PD) are seen as biomarkers of antimalarial drug toxicity. Individual differences in drug response are linked to polymorphisms in the genes encoding these markers. Despite multiple studies on the potential of biomarkers in antimalarial medications, further study is needed to better characterize biomarkers for specific adverse effects (AEs) associated with the use of antimalarial drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Abbreviations

ACTs:: Artemisinin-based combination therapies
AEs:: Adverse effects
AL:: Artemether–Lumefantrine
AS+AQ:: Artesunate + Amodiaquine
AS+MQ:: Artesunate + Mefloquine
AS+SP:: Artesunate + Sulfadoxine–Pyrimethamine
BCRP:: Breast Cancer Resistance Protein
CNS:: Central Nervous System
CTs:: Combination therapies
CYT:: Cytochrome P450
DEAQ:: N-desethylamodiaquine
DHA + PQ:: Dihydroartemisinin–Piperaquine
G6PD:: Glucose -6- Phosphate dehydrogenase
GST:: Glutathione S-transferases
HIV:: Human immunodeficiency virus infection
MDR:: Multidrug transporter
OATP:: Organic anion transporting peptide
OCTs:: Organic cation transporters
PfMDR:: P. falciparun Multidrug Transporter
P-gp:: P-glycoprotein
QNM:: Quinoneimine
SLCO1B1:: Solute carrier organic anion transporter
SP:: Sulfadoxine–Pyrimethamine
UGT:: UDP Glucuronosyltransferase
W.H.O:: World Health Organization

References

Aarnoudse ALHJ, van Schaik RHN, Dieleman J, et al. MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clin Pharmacol Ther. 2006;80:367–74. https://doi.org/10.1016/J.CLPT.2006.07.003.
Article CAS PubMed Google Scholar
Abolaji AO, Eteng MU, Omonua O, Adenrele Y. Influence of coadministration of artemether and lumefantrine on selected plasma biochemical and erythrocyte oxidative stress indices in female Wistar rats. Hum Exp Toxicol. 2013;32:206–15. https://doi.org/10.1177/0960327112464666.
Article CAS PubMed Google Scholar
Adam A. Linkage between deficiency of Glucose-6-phosphate dehydrogenase and colour-blindness. Nature. 1894765. 1961;189:686. https://doi.org/10.1038/189686a0.
Article CAS PubMed Google Scholar
Alisky JM, Chertkova EL, Iczkowski KA. Drug interactions and pharmacogenetic reactions are the basis for chloroquine and mefloquine-induced psychosis. Med Hypotheses. 2006;67:1090–4. https://doi.org/10.1016/J.MEHY.2006.01.059.
Article CAS PubMed Google Scholar
Alkadi HO. Antimalarial drug toxicity: a review. Chemotherapy. 2007;53:385–91. https://doi.org/10.1159/000109767.
Article CAS PubMed Google Scholar
Aminake M, Pradel G. Antimalarial drugs resistance in plasmodium falciparum and the current strategies to overcome them. Microb Pathog Strateg Combat Sci Technol Educ. 2013;1:269–82.
Google Scholar
Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in plasmodium falciparum malaria. N Engl J Med. 2014;371:411–23. https://doi.org/10.1056/NEJMOA1314981/SUPPL_FILE/NEJMOA1314981_DISCLOSURES.PDF.
Article PubMed PubMed Central Google Scholar
Audu D, Idowu AB, Idowu OA, et al. Haematological alteration and histopathology of vital organs of pups delivered by mice infected with Plasmodium berghei during the second and third stage of pregnancy. Anim Res Int. 2021;17:3845–53.
Google Scholar
Bateman DN, Dyson EH. Quinine toxicity. Advers Drug React Acute Poisoning Rev. 1986;5:215–33.
CAS Google Scholar
Choudhry VP, Ghafary A, Zaher M, et al. Drug-induced haemolysis and renal failure in children with glucose-6-phosphate dehydrogenase deficiency in Afghanistan. Ann Trop Paediatr. 1990;10:335–8. https://doi.org/10.1080/02724936.1990.11747454.
Article CAS PubMed Google Scholar
Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet. 1996;31:257–74. https://doi.org/10.2165/00003088-199631040-00003.
Article CAS PubMed Google Scholar
Elewa H, Wilby KJ. A review of pharmacogenetics of Antimalarials and associated clinical implications. Eur J Drug Metab Pharmacokinet. 2017;42:745–56. https://doi.org/10.1007/S13318-016-0399-1.
Article CAS PubMed Google Scholar
Ericsson T, Sundell J, Torkelsson A, et al. Effects of artemisinin antimalarials on cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapies. Xenobiotica. 2014;44:615–26. https://doi.org/10.3109/00498254.2013.878815.
Article CAS PubMed Google Scholar
Fanello CI, Karema C, Avellino P, et al. High risk of severe anaemia after chlorproguanil-dapsone+Artesunate antimalarial treatment in patients with G6PD (A-) deficiency. PLoS One. 2008;3:e4031. https://doi.org/10.1371/JOURNAL.PONE.0004031.
Fromm MF, Kim RB, Stein CM, et al. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999;99:552–557. https://doi.org/10.1161/01.CIR.99.4.552.
Gatton ML, Martin LB, Cheng Q. Evolution of resistance to sulfadoxine-pyrimethamine in plasmodium falciparum. Antimicrob Agents Chemother. 2004;48:2116–23. https://doi.org/10.1128/AAC.48.6.2116-2123.2004/FORMAT/EPUB.
Article CAS PubMed PubMed Central Google Scholar
Giao P, De Vries PJ. Pharmacokinetic interactions of antimalarial agents. Clin Pharmacokinet. 2001;40:343–73. https://doi.org/10.2165/00003088-200140050-00003.
Article CAS PubMed Google Scholar
Gil J, Gil Berglund E, for correspondence A. CYP2C8 and antimalaria drug efficacy. Pharmacogenomics. 2007;8:187–98. https://doi.org/10.2217/14622416.8.2.187.
Article CAS PubMed Google Scholar
Gómez-Saladín E, Fryauff DJ, Taylor WRJ, et al. Plasmodium falciparum mdr1 mutations and in vivo chloroquine resistance in Indonesia. Am J Trop Med Hyg. 1999;61:240–4. https://doi.org/10.4269/AJTMH.1999.61.240.
Article PubMed Google Scholar
Grant DM. Pharmacogenetics. Fetal Neonatal Physiol. 2017:222–9. https://doi.org/10.1016/B978-0-323-35214-7.00021-4.
Hall AH, Kulig KW, Rumack BH. Drug- and chemical-induced Methaemoglobinaemia: clinical features and management. Med Toxicol. 1986;1:253–60. https://doi.org/10.1007/BF03259842.
Article CAS PubMed Google Scholar
Harrison AC, Kitteringham NR, Clarke JB, Park BK. The mechanism of bioactivation and antigen formation of amodiaquine in the rat. Biochem Pharmacol. 1992;43:1421–30. https://doi.org/10.1016/0006-2952(92)90198-R.
Article CAS PubMed Google Scholar
Hayeshi R, Masimirembwa C, Mukanganyama S, Ungell ALB. The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux. Eur J Pharm Sci. 2006;29:70–81. https://doi.org/10.1016/J.EJPS.2006.05.009.
Article CAS PubMed Google Scholar
Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin Pharmacol Ther. 2005;78:260–77. https://doi.org/10.1016/J.CLPT.2005.05.011.
Article CAS PubMed Google Scholar
Ilett K, Ethell B, Maggs J, et al. Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. ASPET; 2002.
Book Google Scholar
Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006;234:4–33. https://doi.org/10.1016/J.CANLET.2005.06.051.
Article CAS PubMed Google Scholar
Kerb R, Fux R, Mörike K, et al. Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Infect Dis. 2009;9:760–74. https://doi.org/10.1016/S1473-3099(09)70320-2.
Article CAS PubMed Google Scholar
Kiang TKL, Wilby KJ, Ensom MHH. Clinical pharmacokinetic drug interactions associated with artemisinin derivatives and HIV-antivirals. Clin Pharmacokinet. 2014;53:141–53. https://doi.org/10.1007/S40262-013-0110-5.
Article CAS PubMed Google Scholar
Lee SJ, Ter Kuile FO, Price RN, et al. Adverse effects of Mefloquine for the treatment of uncomplicated malaria in Thailand: a pooled analysis of 19, 850 individual patients. PLoS One. 2017;12. https://doi.org/10.1371/journal.pone.0168780.
Lehne G. P-glycoprotein as a drug target in the treatment of multidrug resistant cancer. Curr Drug Targets. 2005;1:85–99. https://doi.org/10.2174/1389450003349443.
Article Google Scholar
Lewis DFV. 57 varieties: the human cytochromes P450. Pharmacogenomics. 2004;5:305–18. https://doi.org/10.1517/PHGS.5.3.305.29827.
Article CAS PubMed Google Scholar
Li XQ, Björkman A, Andersson TB, et al. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther. 2002;300:399–407. https://doi.org/10.1124/JPET.300.2.399.
Article CAS PubMed Google Scholar
Luzzatto L, Seneca E. G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. Br J Haematol. 2014;164:469–80. https://doi.org/10.1111/BJH.12665.
Article CAS PubMed PubMed Central Google Scholar
Marwa KJ, Schmidt T, Sjögren M, et al. Cytochrome P450 single nucleotide polymorphisms in an indigenous Tanzanian population: a concern about the metabolism of artemisinin-based combinations. 2014. https://doi.org/10.1186/1475-2875-13-420.
Mirghani RA, Sayi J, Aklillu E, et al. CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population. Pharmacogenet Genomics. 2006;16:637–45. https://doi.org/10.1097/01.FPC.0000230411.89973.1B.
Article CAS PubMed Google Scholar
Mirghani RA, Yasar Ü, Zheng T, et al. Enzyme kinetics for the formation of 3-hydroxyquinine and three new metabolites of quinine in vitro; 3-hydroxylation by CYP3A4 is indeed the major metabolic pathway. Drug Metab Dispos. 2002;30:1368–71. https://doi.org/10.1124/DMD.30.12.1368.
Article CAS PubMed Google Scholar
Noedl H, Allmendinger T, Prajakwong S, et al. Desbutyl-Benflumetol, a novel antimalarial compound: in vitro activity in fresh isolates of plasmodium falciparum from Thailand. Antimicrob Agents Chemother. 2001;45:2106–9. https://doi.org/10.1128/AAC.45.7.2106.
Article CAS PubMed PubMed Central Google Scholar
Oerlemans R, Van Der Heijden J, Vink J, et al. Acquired resistance to chloroquine in human CEM T cells is mediated by multidrug resistance-associated protein 1 and provokes high levels of cross-resistance to glucocorticoids. Arthritis Rheum. 2006;54:557–68. https://doi.org/10.1002/ART.21569.
Article CAS PubMed Google Scholar
Packard RM. The origins of antimalarial-drug resistance. N Engl J Med. 2014;371:397–9. https://doi.org/10.1056/NEJMP1403340/SUPPL_FILE/NEJMP1403340_DISCLOSURES.PDF.
Article CAS PubMed Google Scholar
Parikh S, Ouedraogo JB, Goldstein JA, et al. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther. 2007;82:197–203. https://doi.org/10.1038/SJ.CLPT.6100122.
Article CAS PubMed Google Scholar
Pernaute-Lau L, Camara M, Nóbrega de Sousa T, et al. An update on pharmacogenetic factors influencing the metabolism and toxicity of artemisinin-based combination therapy in the treatment of malaria. Expert Opin Drug Metab Toxicol. 2022;18:39–59. https://doi.org/10.1080/17425255.2022.2049235.
Article CAS PubMed Google Scholar
Phillips-Howard PA, ter Kuile FO. CNS adverse events associated with antimalarial agents: fact or fiction? Drug Saf. 1995;12:370–83. https://doi.org/10.2165/00002018-199512060-00003.
Article CAS PubMed Google Scholar
Pongtavornpinyo W, Yeung S, Hastings IM, et al. Malaria journal spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies. Malaria J. 2008; https://doi.org/10.1186/1475-2875-7-229.
Premji Z, Umeh RE, Owusu-Agyei S, et al. Chlorproguanil−Dapsone−Artesunate versus Artemether−Lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated plasmodium falciparum malaria. PLoS One. 2009;4:e6682. https://doi.org/10.1371/JOURNAL.PONE.0006682.
Article PubMed PubMed Central Google Scholar
Price RN, Uhlemann AC, Brockman A, et al. Mefloquine resistance in plasmodium falciparum and increased pfmdr1 gene copy number. Lancet. 2004;364:438–47. https://doi.org/10.1016/S0140-6736(04)16767-6.
Article CAS PubMed PubMed Central Google Scholar
Pussard E, Merzouk M, Barennes H. Increased uptake of quinine into the brain by inhibition of P-glycoprotein. Eur J Pharm Sci. 2007;32:123–7. https://doi.org/10.1016/J.EJPS.2007.06.007.
Article CAS PubMed Google Scholar
Saifi MA, Beg T, Harrath AH, et al. Antimalarial drugs: mode of action and status of resistance. Afr J Pharm Pharmacol. 2013;7:148–56. https://doi.org/10.5897/AJPPX12.015.
Article Google Scholar
Scholar E. Antimalarial agents. xPharm Compr Pharmacol. 2007:Ref 1–3. https://doi.org/10.1016/B978-008055232-3.61023-2.
Shah RR. Pharmacogenetics in drug regulation: promise, potential and pitfalls. Philos Trans R Soc B Biol Sci. 2005;360:1617–38. https://doi.org/10.1098/RSTB.2005.1693.
Article CAS Google Scholar
Shimizu S, Atsumi R, Kenichi, et al. Metabolism-dependent hepatotoxicity of amodiaquine in glutathione-depleted mice. Arch Toxicol. 2009;83. https://doi.org/10.1007/s00204-009-0436-9.
Sortica VA, Lindenau JD, Cunha MG, et al. The effect of SNPs in CYP450 in chloroquine/primaquine plasmodium vivax malaria treatment. Pharmacogenomics. 2016;17:1903–11. https://doi.org/10.2217/PGS-2016-0131/ASSET/IMAGES/LARGE/FIGURE3.JPEG.
Article CAS PubMed Google Scholar
Sortica VA, Lindenau JD, Cunha MG, et al. SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in plasmodium vivax malaria. Pharmacogenomics. 2017;18:1401–11. https://doi.org/10.2217/pgs-2017-0077.
Article CAS Google Scholar
Svensson USH, Ashton M. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br J Clin Pharmacol. 1999;48:528–35. https://doi.org/10.1046/j.1365-2125.1999.00044.x.
Article CAS PubMed PubMed Central Google Scholar
Taylor WRJ, White NJ. Antimalarial drug toxicity: a review. Drug Saf. 2004;27:25–61. https://doi.org/10.2165/00002018-200427010-00003.
Article CAS PubMed Google Scholar
Valko M, Leibfritz D, Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39:44–84. https://doi.org/10.1016/j.biocel.2006.07.001.
Article CAS PubMed Google Scholar
Wangdi K, Furuya-Kanamori L, Clark J, et al. Comparative effectiveness of malaria prevention measures: a systematic review and network meta-analysis. Parasit Vectors. 2018;11. https://doi.org/10.1186/S13071-018-2783-Y.
White NJ, Pukrittayakamee S, Hien TT, et al. Malaria. Lancet. 2014;383:723–35. https://doi.org/10.1016/S0140-6736(13)60024-0.
Article PubMed Google Scholar
WHO. WHO Guidelines for malaria treatment 2021;11.
Google Scholar
WHO (2020) The potential impact of health service disruptions on the burden of malaria.
Google Scholar
Wilby KJ, Ensom MHH. Pharmacokinetics of antimalarials in pregnancy: a systematic review. Clin Pharmacokinet. 2011;50:705–23. https://doi.org/10.2165/11594550-000000000-00000.
Article CAS PubMed Google Scholar
Wilson CM, Serrano AE, Wasley A, et al. Amplification of a gene related to mammalian mdr genes in drug-resistant plasmodium falciparum. Science (80–). 1989;244:1184–6. https://doi.org/10.1126/SCIENCE.2658061.
Article CAS Google Scholar
Winstanley P, Ward S, Snow R, Breckenridge A. Therapy of falciparum malaria in sub-Saharan Africa: from molecule to policy. Clin Microbiol Rev. 2004;17:612–37. https://doi.org/10.1128/CMR.17.3.612-637.2004/ASSET/918DD5A3-FF63-4459-9BE7-F98EEAD06CC6/ASSETS/GRAPHIC/ZCM0030420990004.JPEG.
Article CAS PubMed PubMed Central Google Scholar
Yeung S, Patouillard E, Allen H, Socheat D. Socially-marketed rapid diagnostic tests and ACT in the private sector: ten years of experience in Cambodia. Malar J. 2011:10. https://doi.org/10.1186/1475-2875-10-243.
Youngster I, Arcavi L, Schechmaster R, et al. Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review. Drug Saf. 2010;33:713–26. https://doi.org/10.2165/11536520-000000000-00000.
Article CAS PubMed Google Scholar
Yusof W, Hua GS. Gene, ethnic and gender influences predisposition of adverse drug reactions to artesunate among Malaysians. Toxicol Mech Methods. 2012;22:184–92. https://doi.org/10.3109/15376516.2011.623331.
Article CAS PubMed Google Scholar
Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008;392:1093–108. https://doi.org/10.1007/S00216-008-2291-6.
Article CAS PubMed Google Scholar
Zhang Y, Den Braver-Sewradj SP, Vos JC, et al. Human glutathione S-transferases-and NAD(P)H:quinone oxidoreductase 1-catalyzed inactivation of reactive quinoneimines of amodiaquine and N-desethylamodiaquine: possible implications for susceptibility to amodiaquine-induced liver toxicity. Toxicol Lett. 2017;275:83. https://doi.org/10.1016/j.toxlet.2017.05.003.
Article CAS PubMed Google Scholar

Download references

Author information

Authors and Affiliations

Department of Pure and Applied Zoology, College of Biosciences, Federal University of Agriculture, Abeokuta, Ogun State, Nigeria
David Audu, Olufunmilayo Ajoke Idowu & Adewunmi Babatunde Idowu
School of Life Sciences, University of Westminster, London, UK
Lucy Petagine & Vinood B. Patel

Authors

David Audu
View author publications
You can also search for this author in PubMed Google Scholar
Lucy Petagine
View author publications
You can also search for this author in PubMed Google Scholar
Olufunmilayo Ajoke Idowu
View author publications
You can also search for this author in PubMed Google Scholar
Vinood B. Patel
View author publications
You can also search for this author in PubMed Google Scholar
Adewunmi Babatunde Idowu
View author publications
You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Audu .

Editor information

Editors and Affiliations

Department of Biomedical Sciences, University of Westminster, London, UK
Vinood B. Patel
Sch Biomed & Health Sci, Wilkins Bldg, King's College London Franklin, London, UK
Victor R. Preedy
Department of Medicine, King Abdulaziz Med City, Riyadh, Saudi Arabia
Rajkumar Rajendram

Rights and permissions

Reprints and permissions

Copyright information

About this entry

Cite this entry

Audu, D., Petagine, L., Idowu, O.A., Patel, V.B., Idowu, A.B. (2023). Biomarkers of the Toxic Effects of Chemotherapeutic Agents: A Focus on Antimalarials. In: Patel, V.B., Preedy, V.R., Rajendram, R. (eds) Biomarkers in Toxicology. Biomarkers in Disease: Methods, Discoveries and Applications. Springer, Cham. https://doi.org/10.1007/978-3-030-87225-0_73-2

Download citation

DOI: https://doi.org/10.1007/978-3-030-87225-0_73-2
Received: 06 May 2022
Accepted: 06 May 2022
Published: 12 November 2022
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-87225-0
Online ISBN: 978-3-030-87225-0
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences

Publish with us

Policies and ethics

Chapter history

Latest
Biomarkers of the Toxic Effects of Chemotherapeutic Agents: A Focus on Antimalarials

Published:

12 November 2022

DOI: https://doi.org/10.1007/978-3-030-87225-0_73-2
Original
Biomarkers of the Toxic Effects of Chemotherapeutic Agents: A Focus on Antimalarials

Published:

01 October 2022

DOI: https://doi.org/10.1007/978-3-030-87225-0_73-1